Unknown

Dataset Information

0

Reversal of established liver fibrosis by IC-2-engineered mesenchymal stem cell sheets.


ABSTRACT: Chronic hepatitis viral infection, alcoholic intoxication, and obesity cause liver fibrosis, which progresses to decompensated liver cirrhosis, a disease for which medical demands cannot be met. Since there are currently no approved anti-fibrotic therapies for established liver fibrosis, the development of novel modalities is required to improve patient prognosis. In this study, we clarified the anti-fibrotic effects of cell sheets produced from human bone marrow-derived mesenchymal stem cells (MSCs) incubated on a temperature-sensitive culture dish with the chemical compound IC-2. Orthotopic transplantation of IC-2-engineered MSC sheets (IC-2 sheets) remarkably reduced liver fibrosis induced by chronic CCl4 administration. Further, the marked production of fibrolytic enzymes such as matrix metalloproteinase (MMP)-1 and MMP-14, as well as thioredoxin, which suppresses hepatic stellate cell activation, was observed in IC-2 sheets. Moreover, the anti-fibrotic effect of IC-2 sheets was much better than that of MSC sheets. Finally, knockdown experiments revealed that MMP-14 was primarily responsible for the reduction of liver fibrosis. Here, we show that IC-2 sheets could be a promising therapeutic option for established liver fibrosis.

SUBMITTER: Itaba N 

PROVIDER: S-EPMC6497888 | biostudies-other | 2019 May

REPOSITORIES: biostudies-other

altmetric image

Publications

Reversal of established liver fibrosis by IC-2-engineered mesenchymal stem cell sheets.

Itaba Noriko N   Kono Yohei Y   Watanabe Kaori K   Yokobata Tsuyoshi T   Oka Hiroyuki H   Osaki Mitsuhiko M   Kakuta Hiroki H   Morimoto Minoru M   Shiota Goshi G  

Scientific reports 20190502 1


Chronic hepatitis viral infection, alcoholic intoxication, and obesity cause liver fibrosis, which progresses to decompensated liver cirrhosis, a disease for which medical demands cannot be met. Since there are currently no approved anti-fibrotic therapies for established liver fibrosis, the development of novel modalities is required to improve patient prognosis. In this study, we clarified the anti-fibrotic effects of cell sheets produced from human bone marrow-derived mesenchymal stem cells (  ...[more]

Similar Datasets

| S-EPMC8399086 | biostudies-literature
| S-EPMC6222293 | biostudies-literature
| S-EPMC4639852 | biostudies-other
| S-EPMC5762914 | biostudies-literature
| S-EPMC7347778 | biostudies-literature
| S-EPMC6877761 | biostudies-literature
| S-EPMC4154962 | biostudies-literature
| S-EPMC6203842 | biostudies-other
| S-EPMC7705723 | biostudies-literature
| S-EPMC5155221 | biostudies-other